ad image

Biologics License Application

1 / 1
Amgen
Biosimilar

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

Amgen

PR-M01-19-NI-002Jan 02, 2019
1 / 1